State Street
CMPX icon

State Street’s Compass Therapeutics CMPX Stock Holding History

State Street’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Buy
9,953,653
+3,258,677
+49% +$9.62M ﹤0.01% 2310
2026
Q1 		$35.4M Buy
6,694,976
+1,804,451
+37% +$10.4M ﹤0.01% 1934
2025
Q4 		$26.3M Buy
4,890,525
+1,784,012
+57% +$8.24M ﹤0.01% 2107
2025
Q3 		$10.9M Buy
3,106,513
+1,135,145
+58% +$3.59M ﹤0.01% 2594
2025
Q2 		$5.13M Buy
1,971,368
+21,691
+1% +$44.7K ﹤0.01% 2929
2025
Q1 		$3.7M Buy
1,949,677
+46,669
+2% +$124K ﹤0.01% 2995
2024
Q4 		$2.76M Buy
1,903,008
+39,031
+2% +$64.8K ﹤0.01% 3210
2024
Q3 		$3.43M Buy
1,863,977
+3,808
+0.2% +$4.75K ﹤0.01% 3124
2024
Q2 		$1.86M Buy
1,860,169
+33,992
+2% +$49.6K ﹤0.01% 3342
2024
Q1 		$3.62M Buy
1,826,177
+99,873
+6% +$173K ﹤0.01% 3057
2023
Q4 		$2.69M Sell
1,726,304
-29,809
-2% -$51.6K ﹤0.01% 3217
2023
Q3 		$3.46M Buy
1,756,113
+9,599
+0.5% +$23.7K ﹤0.01% 3096
2023
Q2 		$5.55M Buy
1,746,514
+1,344,201
+334% +$4.22M ﹤0.01% 2945
2023
Q1 		$1.32M Buy
402,313
+132,200
+49% +$519K ﹤0.01% 3453
2022
Q4 		$1.36M Buy
+270,113
New +$1.08M ﹤0.01% 3488

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's CMPX Position: Q2 2026 in Review

State Street increased its Compass Therapeutics (CMPX) stake by 49% in Q2 2026, buying an estimated $9.62M and bringing the position to 9,953,653 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

State Street first reported a position in CMPX in Q4 2022 and has held it in 15 quarters since. The position peaked at $35.4M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • State Street held 9,953,653 shares of Compass Therapeutics worth $21.8M as of Q2 2026.
  • State Street bought 3,258,677 Compass Therapeutics shares in Q2 2026, an estimated $9.62M.
  • Compass Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2310 holding.
  • State Street first reported a position in Compass Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • State Street's Compass Therapeutics position peaked at $35.4M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.